|
1
|
Goldhirsch A, Glick JH, Gelber RD, Coates
AS, Thurlimann B and Senn HJ: Meeting highlights: international
expert consensus on the primary therapy of early breast cancer
2005. Ann Oncol. 16:1569–1583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomssen C and Janicke F: Do we need
better prognostic factors in node-negative breast cancer? Eur J
Cancer. 36:293–298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Talvensaari-Mattila A, Paakko P, Hoyhtya
M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix
metalloproteinase-2 immunoreactive protein: a marker of
aggressiveness in breast carcinoma. Cancer. 83:1153–1162. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li HC, Cao DC, Liu Y, et al: Prognostic
value of matrix metalloproteinases (MMP-2 and MMP-9) in patients
with lymph node-negative breast carcinoma. Breast Cancer Res Treat.
88:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giambernardi TA, Grant GM, Taylor GP, et
al: Overview of matrix metalloproteinase expression in cultured
human cells. Matrix Biol. 16:483–496. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwasaki M, Nishikawa A, Fujimoto T, et al:
Anti-invasive effect of MMI-166, a new selective matrix
metalloproteinase inhibitor, in cervical carcinoma cell lines.
Gynecol Oncol. 85:103–107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato Y, Yamashita T and Ishikawa M:
Relationship between expression of matrix metalloproteinase-2 and
matrix metalloproteinase-9 and invasion ability of cervical cancer
cells. Oncol Rep. 9:565–569. 2002.PubMed/NCBI
|
|
8
|
McMasters KM, Giuliano AE, Ross MI, et al:
Sentinel-lymph-node biopsy for breast cancer - not yet the standard
of care. N Engl J Med. 339:990–995. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Curran S, Dundas SR, Buxton J, Leeman MF,
Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors
of matrix metalloproteinase phenotype identifies poor prognosis
colorectal cancers. Clin Cancer Res. 10:8229–8234. 2004. View Article : Google Scholar
|
|
10
|
Forget MA, Desrosiers RR and Beliveau R:
Physiological roles of matrix metalloproteinases: implications for
tumor growth and metastasis. Can J Physiol Pharmacol. 77:465–480.
1999. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duffy MJ, Maguire TM, Hill A, McDermott E
and O’Higgins N: Metalloproteinases: role in breast carcinogenesis,
invasion and metastasis. Breast Cancer Res. 2:252–257. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giannelli G, Bergamini C, Fransvea E,
Marinosci F, Quaranta V and Antonaci S: Human hepatocellular
carcinoma (HCC) cells require both alpha3beta1 integrin and matrix
metalloproteinases activity for migration and invasion. Lab Invest.
81:613–627. 2001. View Article : Google Scholar
|
|
13
|
Vasala K, Paakko P and
Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive
protein as a prognostic marker in bladder cancer. Urology.
62:952–957. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gerhards S, Jung K, Koenig F, et al:
Excretion of matrix metalloproteinases 2 and 9 in urine is
associated with a high stage and grade of bladder carcinoma.
Urology. 57:675–679. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liabakk NB, Talbot I, Smith RA, Wilkinson
K and Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix
metalloprotease 9 (MMP-9) type IV collagenases in colorectal
cancer. Cancer Res. 56:190–196. 1996.
|
|
16
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davies B, Miles DW, Happerfield LC, et al:
Activity of type IV collagenases in benign and malignant breast
disease. Br J Cancer. 67:1126–1131. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown PD, Bloxidge RE, Anderson E and
Howell A: Expression of activated gelatinase in human invasive
breast carcinoma. Clin Exp Metastasis. 11:183–189. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Di Carlo A, Terracciano D, Mariano A and
Macchia V: Matrix metalloproteinase-2 and matrix
metalloproteinase-9 type IV collagenases in serum of patients with
pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
|
|
20
|
Daniele A, Zito AF, Giannelli G, et al:
Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph
node and serum of patients with metastatic and non-metastatic
breast cancer. Anticancer Res. 30:3521–3527. 2010.PubMed/NCBI
|
|
21
|
Hanemaaijer R, Verheijen JH, Maguire TM,
et al: Increased gelatinase-A and gelatinase-B activities in
malignant vs. benign breast tumors. Int J Cancer. 86:204–207. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zucker S, Hymowitz M, Conner C, et al:
Measurement of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in blood and tissues. Clinical and experimental
applications. Ann NY Acad Sci. 878:212–227. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kjeldsen L, Bjerrum OW, Hovgaard D,
Johnsen AH, Sehested M and Borregaard N: Human neutrophil
gelatinase: a marker for circulating blood neutrophils.
Purification and quantitation by enzyme linked immunosorbent assay.
Eur J Haematol. 49:180–191. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ranuncolo SM, Armanasco E, Cresta C, Bal
De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity
is useful in the follow-up and in the assessment of prognosis in
breast cancer patients. Int J Cancer. 106:745–751. 2003. View Article : Google Scholar : PubMed/NCBI
|
